What are the contraindications for diosmin and hisperidine?

Contraindications for Diosmin and Hesperidin

Based on FDA drug labeling and available clinical evidence, diosmin and hesperidin have no absolute contraindications documented, though caution is warranted in specific populations including pregnant/breastfeeding women, patients with severe hepatic or renal impairment, and those taking medications metabolized by CYP450 enzymes. 1

Documented Contraindications

Absolute Contraindications

• None formally established in FDA labeling or clinical guidelines 1

Relative Contraindications and Cautions

Pregnancy and Lactation:

• Best avoided during pregnancy, particularly first trimester, though no teratogenic effects have been documented in humans 1
• Safety data during breastfeeding are insufficient; use only if benefits clearly outweigh risks

Hepatic Impairment:

• Use with caution in patients with significant liver disease
• Hesperidin may affect CYP450 3A4 metabolism, potentially increasing bioavailability of drugs like diltiazem 1
• Monitor liver function if hepatotoxic chemotherapy is concurrent

Renal Impairment:

• Exercise caution in severe renal dysfunction (CrCl <30 mL/min)
• No specific dose adjustments established, but monitoring recommended 1

Drug Interactions:

• CYP450 enzyme interactions: Diosmin may interfere with CYP2E1 (affecting chlorzoxazone metabolism) and CYP2C9 (affecting diclofenac and metronidazole) 1
• Hesperidin may inhibit CYP450 3A4, increasing levels of drugs metabolized by this pathway
• Grapefruit juice effects on drug metabolism have not been specifically attributed to diosmin/hesperidin but warrant consideration 1

Safety Profile

Clinical Trial Data: Multiple clinical trials (doses 400-5,000 mg/day for up to one year) reported no serious adverse events 1. Common mild adverse effects include:

• Gastrointestinal disturbances (dyspepsia in up to 7% vs ~3.5% placebo)
• Headaches
• Rare: rash (1%), cramping (2%), phlebitis (2%)

Special Populations:

• Elderly patients (≥70 years): No increased adverse event incidence compared to younger populations 1
• Patients with comorbidities (hypertension, atherosclerosis, diabetes): No significant difference in adverse event rates 1

Clinical Considerations

When prescribing diosmin/hesperidin:

1. Screen for hepatic/renal impairment before initiating therapy
2. Review medication list for CYP450-metabolized drugs (particularly 2C9, 2E1, 3A4 substrates)
3. Counsel pregnant/breastfeeding women about limited safety data
4. Monitor for mild GI symptoms in first weeks of therapy; these typically do not require discontinuation
5. Consider lower starting doses in patients with multiple comorbidities or polypharmacy

The excellent safety profile across extensive clinical trials supports use in most patient populations, but the lack of formal contraindication data should not preclude clinical judgment in high-risk scenarios 1, 2.